In vitro metabolism of indiplon and an assessment of its drug interaction potential

Xenobiotica

Volumn 37, Issue 7, 2007, Pages 736-752

  Madan, A ^a   Fisher, A ^a   Jin, L ^a   Chapman, D ^a   Bozigian, H P ^a  

^a NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

CYP; CYP3A4 5; Cytochrome P450; Deacetylation; Demethylation; Drug interactions; Indiplon; Inhibition of cytochrome P450

Indexed keywords

4 NITROPHENYLACETIC ACID; ACETIC ACID DERIVATIVE; CARBOXYLESTERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; FURAFYLLINE; INDIPLON; KETOCONAZOLE; N DESACETYL INDIPLON; N DESMETHYL INDIPLON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; LIVER MICROSOME;

BENZODIAZEPINES; CARBOXYLIC ESTER HYDROLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES; MICROSOMES, LIVER; THIOPHENES;

EID: 34447309312     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701433054     Document Type: Article

References (26)

1. Bozigian H, Chen TK, Gately N, Boyd M. 2005. Indiplon dose-dependent pharmacokinetics. Journal of Clinical Pharmacology 45:1078.
2. Bucholtz ML, Light RJ. 1976. Hydrolysis of 13-sophorosyloxydocosanoic acid esters by acetylcarboxylesterases isolated from Candida bororiensis. Journal of Biological Chemistry 25:431-437.
3. Chauret N, Gauthier A, Nicoll-Griffith DA. 1998. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metabolism and Disposition 26:1-4.
4. Corrigan B, Abel B, Hershberger E, Bozigian H, Madan A, Chen TK, Gately N, Boyd M. 2005. Indiplon with warfarin, theophylline and digozin: Lack of pharmacokinetic interactions. Journal of Clinical Pharmacology 45:1077.
5. Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follath F. 1995. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. European Journal of Clinical Pharmacology 48:367-371.
6. Jochelson P, Chen TK, Farber R, Campbell B. 2003. Lack of pharmacological and pharmacokinetic tolerance following repeat dosing of indiplon (NBI-34060). Sleep 26:A85.
7. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, Watabe T. 1999. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metabolism and Disposition 27:422-28.
8. Kitada M, Kato T, Ohmori S, Kamataki T, Itahashi K, Guengerich FP, Rikhisa T, Kanakubo Y. 1992. Immunochemical characterization and toxicological significance of P-450HFLa purified from human fetal livers. Biochimica et Biophysica Acta 1117:301-305.
9. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA. 2002. Metabolism of zaleplon by human liver: Evidence for involvement of aldehyde oxidase. Xenobiotica 32:835-847.
10. Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. 2002. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodriguez AD, editor. Drug-drug interactions. Drugs and the pharmaceutical sciences. Vol. 116. New York: Marcel and Dekker. pp 217-294.
11. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS, Boobis A. 1993. Human hepatic CYP1A1 and CYP1A2 content, determined with specific antipeptide antibodies, correlates with the mutagenic activation of PhIP. Carcinogenesis 14:585-592.
12. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A. 1996. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Archives of Biochemistry and Biophysics 331:145-169.
13. A receptors. Journal of Pharmacology and Experimental Therapeutics 317:369-377.
14. Pichard L, Gillet G, Bonfils C, Domergue J, Thenot JP, Maurel P. 1995. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metabolism and Disposition 23:1253-1262.
15. Preuss CV, Svensson CK. 1996. Arylacetamide deacetylase activity towards monoacetyldapsone. Species comparison, factors that influence activity, and comparison with 2-acetylaminofluorene and p-nitrophenyl acetate hydrolysis. Biochemical Pharmacology 51:1661-1668.
16. Probst MR, Beer M, Beer D, Jeno P, Meyer UA, Gasser R. 1994. Human liver arylacetamide deacetylase. Molecular cloning of a novel esterase involved in the metabolic activation of arylamine carcinogens with high sequence similarity to hormone-sensitive lipase. Journal of Biological Chemistry 269:21650-21656.
17. Renwick AB, Mistry H, Ball SE, Walters DG, Kao J, Lake BG. 1998. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 28:337-348.
18. Robertson P, DeCory HH, Madan A, Parkinson A. 2000. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metabolism and Disposition 28:664-671.
19. Rowland M, Matin SB. 1973. Kinetics of drug-drug interactions. Journal of Pharmacokinetics and Biopharmaceuticals 1:553-567.
20. Satoh T, Hosokawa M. 1998. The mammalian carboxylesterase: From molecules to functions. Annual Review of Pharmacology and Toxicology 38:257-288.
21. Shuetz JD, Kauma S, Guzelian PS. 1993. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. Journal of Clinical Investigation 92:1018-1024.
22. Thummel KE, Kunze KL, Shen DD. 2000. Metabolically-based drug-drug interactions: Principles and mechanisms. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. London: Lippincott, Williams & Wilkins. pp 3-20.
23. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. 1997. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
24. Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. 1999. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology 48:89-97.
25. Walker CH, Mackness MI. 1983. Esterases: Problems of identification and classification. Biochemical Pharmacology 32:3265-3269.
26. Zhang J, Burnell JC, Dumaual N, Bosron WF. 1999. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. Journal of Pharmacology and Experimental Therapeutics 290:314-318.